The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
The company had achieved the highest "A" rating in Climate Change
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Roche says its new assay “resolves this challenge by delivering accurate and specific results
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Subscribe To Our Newsletter & Stay Updated
